GID4

Across TCGA pan-cancer cohorts, GID4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GID4 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GID4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GID4 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where GID4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.365	0.580	.003	37	view →
HNSC	DFS	Median	II,III,IV	0.987	0.889	.001	19	view →
UCEC	DFS	Median	All	0.943	0.777	.015	4	view →
GBM	OS	Median	All	0.892	0.645	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GID4–PDAC (OS)

Open the PDAC breakdown →